BRCA1 and ovarian carcinoma: The finding that niraparib decreased replication fork restart (Fig. 2a) and increased genomic instability (Fig. 2c, d) is consistent with the molecular mechanism of synthetic lethality in PARP1 inhibition in BRCA1 and 2-deficient breast and ovarian cancers [12, 13, 18].